ABHD6 as a novel drug target for obesity, non-alcoholic fatty liver disease (NASH) and cardiovascular disease (CVD)

Obesity, type 2 diabetes (T2D) and heart diseases have skyrocketed. Controlling glucose usage and insulin balance can substantially decrease the morbidity and improve the quality of life in affected individuals. Dysfunctional insulin action and energy balance in the body is associated with excessive non-adipose fat storage, particularly in the liver, and elevated circulating lipids, which […]

Read More